The main objective was to assess the clinical benefits and hazards of using etanercept and infliximab in rheumatoid arthritis.
deviation (SD) was taken directly from the reported results or derived from the standard error of the mean, confidence intervals (CIs) or P-values. The SD from baseline data was used when the SD for the final results was not available. Where the SD could not be directly estimated from the studies, it was imputed from the baseline SDs from trials recruiting a similar patient population.
Methods of synthesis
How were the studies combined? Initially all studies were tabulated and described individually in the text of the review. Meta-analyses were then conducted on what were considered to be six main outcomes. Three outcomes were continuous (Health Assessment Questionnaire, patient global assessment and swollen joint counts) and three were binary (ACR20, ACR50, ACR70). Where a continuous outcome was reported on the same scale, the results were presented as a weighted mean difference (WMD). Where different scales were used, the standardised mean difference was calculated. Binary outcomes were presented as the relative risk (RR) and risk difference (RD). All were reported with 95% CIs.
A fixed-effect model was used unless the trials were statistically heterogeneous, in which case a random-effects model was also used. The most conservative result was presented.
How were differences between studies investigated?
The authors carried out a chi-squared test to determine the presence of statistical heterogeneity in the meta-analysis.
Results of the review
Ten RCTs were included, four of infliximab therapy (n=602) and six of etanercept therapy (n=1,694).
All 10 RCTs were of a high quality, scoring 5 out of 5 on the Jadad checklist.
ACR20.
Etanercept versus placebo (4 studies): the RR was4.29 (95% CI: 3.12, 5.88) and the RD was 0.44 (95% CI: 0.39, 0.49). Etancercept showed a statistically significant effect over placebo.
Infliximab versus placebo (4 studies): the RR was 3.55 (95% CI: 2.33, 5.41) and the RD was 0.37 (95% CI: 0.25, 0.48). Infliximab showed a statistically significant effect over placebo.
All arms combined versus placebo: the RR was 4.01 (95% CI: 3.12, 5.17) and the RD was 0.41 (95% CI: 0.35, 0.46). All treatment arms combined showed a statistically significant effect over placebo.
ACR50.
Etanercept versus placebo (4 studies): the RR was 5.90 (95% CI: 3.44, 10.12) and the RD was 0.25 (95% CI: 0.20, 0.29). Etancercept showed a statistically significant effect over placebo.
Infliximab versus placebo (4 studies): the RR was 4.30 (95% CI: 2.37, 7.80) and the RD was 0.26 (95% CI: 0.20, 0.32). Infliximab showed a statistically significant effect over placebo.
All arms combined versus placebo: the RR was 5.17 (95% CI: 3.46, 7.71) and the RD was 0.25 (95% CI: 0.22, 0.29). All treatment arms combined showed a statistically significant effect over placebo.
ACR70.
Etanercept versus placebo (1 study): the RR was 9.60 (95% CI: 2.74, 33.68) and the RD was 0.10 (95% CI: 0.06, 0.13). Etancercept showed a statistically significant effect over placebo.
Infliximab versus placebo (1 study): the RR was 7.76 (95% CI: 1.94, 31.15) and the RD was 0.15 (95% CI: 0.10, 0.20). Infliximab showed a statistically significant effect over placebo. All arms combined versus placebo: the RR was 8.73 (95% CI: 3.44, 22.15) and the RD was 1.12 (95% CI: 0.07, 0.16). All treatment arms combined showed a statistically significant effect over placebo, although there was some statistical heterogeneity between the studies.
Health Assessment Questionnaire.
Etanercept versus placebo (3 studies): the WMD was -0.48 (95% CI: -0.71, -0.25). Etancercept showed a statistically significant effect over placebo, although the studies were heterogeneous.
Infliximab versus placebo (1 study): the WMD was -0.20 (95% CI: -0.34, -0.06). Infliximab showed a statistically significant effect over placebo.
All arms combined versus placebo: the WMD was -0.40 (95% CI: -0.62, -0.18). All treatment arms combined showed a statistically significant effect over placebo, although the studies were heterogeneous.
Patient global assessment.
Etanercept versus placebo (4 studies): the WMD was -2.25 (95% CI: -2.87, -1.63). Etancercept showed a statistically significant effect over placebo, although the studies were heterogeneous.
Infliximab versus placebo (1 study): the WMD was -1.50 (95% CI: -2.13, -0.87). Infliximab showed a statistically significant effect over placebo.
All arms combined versus placebo: the WMD was -2.12 (95% CI: -2.68, -1.55). All treatment arms combined showed a statistically significant effect over placebo, although the studies were heterogeneous.
Swollen joint counts.
Etanercept versus placebo (5 studies): the WMD was -6.58 (95% CI: -12.02, -1.15). Etancercept showed a statistically significant effect over placebo, although the studies were heterogeneous.
Infliximab versus placebo (3 studies): the WMD was -9.48 (95% CI: -14.01, -4.94). Infliximab showed a statistically significant effect over placebo, although the studies were heterogeneous.
All arms combined versus placebo: the WMD was -7.77 (95% CI: -11.37, -4.17). All treatment arms combined showed a statistically significant effect over placebo, although the studies were heterogeneous.
Etanercept versus methotrexate (1 study).
ACR20: for combined etanercept arms versus methotrexate, the RR was 1.03 (95% CI: 0.9, 1.17). For etanercept 25 mg versus methotrexate, the RR was 1.12 (95% CI: 0.96, 1.29). Neither dose showed a statistically significant treatment effect over methotrexate.
Serious adverse events occurred infrequently and were comparable to placebo.
Cost information
After reviewing the economic literature and pharmaceutical industry submissions, the authors concluded that the annual drug costs are around £9,600 for infliximab and £8,800 for etanercept compared with £3,100 for cyclosporin, the most expensive conventional disease-modifying anti-rheumatic drug (DMARD). A sensitivity analysis from a provisional model gave figures ranging from £47,000 to £128,000 for etanercept, and from £62,000 to £169,000 for infliximab, if used last in the sequence of DMARDs.
